Iovance Biotherapeutics: High-Risk Cancer Stock Potential
A bold, high‑risk biotech bet can pay off with patience and discipline. This article breaks down iovance biotherapeut...
Looking to earn more? Discover simple ways to integrate money-making activities into your daily routine.
27,728 articlesA bold, high‑risk biotech bet can pay off with patience and discipline. This article breaks down iovance biotherapeut...
Friday brought a sharp move for algonquin power utilities stock as investors digested a guidance miss for 2027. This ...
A top Nomura strategist says equities are priced for chaos, but the odds of a sweeping market crash remain low as dat...
Tesla and Google unveil a cross-industry effort aimed at reducing household energy costs through grid modernization a...
As advertisers shift to privacy-first strategies, Viant Technology (DSP) 2025 presents both opportunities and risks. ...
BlackRock launched its ETHB staked Ethereum ETF, drawing early traction with a $15.5 million first-day volume as inst...
Meta Platforms is considering cutting up to 20% of its workforce to fund AI infrastructure through 2028. The move mir...
CytomX Therapeutics delivered a sharp rally after promising Phase 1 data for its colorectal cancer program. This arti...
DeFi founders argue that tokenized assets are the next growth lever, linking real-world value to on-chain liquidity. ...
Sunoco LP is redefining its business, shifting from fueling pumps to a broader energy platform. With 2026 EBITDA guid...
Alibaba.com's leader previews a future where a single founder can run a global B2B business with AI handling the heav...
AI’s endless appetite for compute and memory is shifting demand away from PCs. Prices rise, supply tightens, and inve...